Heart failure & cardiomyopathies
Guideline-Directed Medical Therapy After Revascularization and Outcomes in Ischaemic Cardiomyopathy
Authors' conclusion
GDMTi was associated with lower unadjusted mortality, though not significant after adjustment. GDMTi combined with CABG showed the best outcomes. The use of GDMTi improved over time.
Study context
- Population
- One-year survivors with de novo ischaemic HFrEF (LVEF ≤40%) and coronary artery disease (CAD) revascularised shortly after index heart failure (HF) admissionof 409 with HFrEF and CAD
- Participants
- 275 survivors
- Comparison
- GDMTi vs non-GDMTi after revascularisation
- Primary endpoint
- All-cause and CV mortality by GDMTi
- Follow-up
- Median 41.6 months
Methodological detailslandmark analysis
- Landmark analysis
Primary result
As reported in the abstract
GDMTi vs non-GDMTiHazard ratio (95% CI)P value
All-cause mortality, adjusted
0.63(0.39–1.02)
P = 0.06CV mortality, adjusted
0.62(0.33–1.18)
P = 0.14Secondary outcomes
Mortality with GDMTi/CABG
| HR (95% CI) | P value | ||
|---|---|---|---|
| GDMTi/CABGAll-cause mortality | 0.42 (0.20–0.87) | P = 0.02 | |
| GDMTi/CABGCV mortality | 0.40 (0.16–0.99) | P = 0.05 | |
| 0.10.31310Hazard ratio (log scale) |
Temporal trend in GDMTi
- GDMTi use increased progressively over the study period
Original publication
Guideline-Directed Medical Therapy After Revascularization and Outcomes in Ischaemic Cardiomyopathy. ESC Heart Fail. Published 17 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →